ArticleJACC. Asia2022
Residual Inflammatory Risk and its Association With Events in East Asian Patients After Coronary Intervention.
Article in JACC. Asia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04650529 (G-NUH), which is not on this map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
G-NUH (Gyeongsang National University Hospital) Registry
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Residual inflammatory risk and clinical outcomes after contemporary percutaneous coronary intervention: a systematic review and meta-analysis.Scientific reports · 2026Pooled it
- Prognostic significance of 1-year versus baseline high-sensitivity C-reactive protein after acute myocardial infarction: nationwide landmark results.The Korean journal of internal medicine · 2026Article
- CRP Cutoff Value in East Asians With Coronary Heart Disease: A Systematic Review and Meta-Analysis.JACC. Asia · 2026Article
- Residual inflammatory risk as a predictor of cardiometabolic multi-morbidity: results from three prospective cohorts.Journal of health, population, and nutrition · 2026Article
- Persistent residual inflammatory risk at 1 month after contemporary PCI: rationale for routine hsCRP reassessment and dual-target therapy.Frontiers in immunology · 2026Review
- Comparative Evaluation of Prolonged Dual Antiplatelet Therapy versus Conventional Regimens on Prognosis in Patients with High Residual Inflammatory Risk: Results from a Prospective Observational Study.Journal of inflammation research · 2026Article
- Inflammatory and Bleeding Risks on Clinical Outcomes in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention.Thrombosis and haemostasis · 2025Article
- Residual Inflammatory and Cholesterol Risk and the Association With Recurrent Cardiovascular Events in East Asian Patients After Percutaneous Coronary Intervention.Reviews in cardiovascular medicine · 2025Article
- Position Statement on Antiplatelet Therapy for East Asians With Coronary Artery Disease: 2025 Update.JACC. Asia · 2025Review
- Association of Decreased Fecal Microbiota Akkermansia with Increased High-Sensitivity C-Reactive Protein Levels in Patients with Unstable Angina.Current medical science · 2025Article
- Significance of Residual Inflammatory Risk and Persistent Inflammation in Patients with Myocardial Infarction with Nonobstructive Coronary Arteries.Journal of inflammation research · 2025Article
- Systemic inflammation and health outcomes in patients receiving treatment for atherosclerotic cardiovascular disease.European heart journal · 2024Observational
- Different Oxidative Stress and Inflammation Patterns of Diseased Left Anterior Descending Coronary Artery versus Internal Thoracic Artery.Antioxidants (Basel, Switzerland) · 2024Article
- Residual Inflammatory Risk in Outcomes of Chinese Patients After Percutaneous Coronary Intervention.JACC. Asia · 2024Article
- Identifying the vulnerable patient: pericoronary Adipose tissue attenuation on computed tomography.Journal of thrombosis and thrombolysis · 2024Article
- Effects of PCSK9 on thrombosis and haemostasis in a variety of metabolic states: Lipids and beyond (Review).International journal of molecular medicine · 2024Review
- Inflammation and platelet reactivity during adjunctive colchicine versus aspirin in patients with acute coronary syndrome treated with potent P2Y12 inhibitor.Frontiers in medicine · 2024Article
- Prognostic significance of inflammation in patients with coronary artery disease at low residual inflammatory risk.iScience · 2023Article
- Residual Inflammatory Risk After Percutaneous Coronary Intervention: Underappreciated But Modifiable.JACC. Asia · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: East Asian population has a low level of inflammation compared with Western population. The prognostic implication of residual inflammatory risk (RIR) remains uncertain in East Asians. Objectives: This study sought to provide an analysis to estimate early-determined RIR and its association with clinical outcomes in East Asian patients with coronary artery disease (CAD). Methods: In an East Asian registry including patients with CAD undergoing percutaneous coronary intervention (PCI) (n = 4,562), RIR status was determined by measuring high-sensitivity C-reactive protein (hsCRP) serially at admission and at 1-month follow-up. Patients were stratified into 4 groups according to hsCRP criteria (≥2 mg/L): 1) persistent low RIR (low Results: In our cohort, median levels of hsCRP were significantly decreased over time (1.3 to 0.9 mg/L; Conclusions: Approximately one-fifth of East Asian patients with CAD have persistent high RIR, which shows the close association with occurrence of ischemic and bleeding events. (Gyeongsang National University Hospital Registry [GNUH]; NCT04650529).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.